# Bionano Genomics, Inc.: overview BNGO · Nasdaq · CIK 1411690 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bngo.md) · [Financials](/companies/bngo/financials.md) · [Filings](/companies/bngo/filings.md) · [Insiders](/companies/bngo/insiders.md) Latest reported revenue: [$8.2m](/filings/0001411690-26-000044.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001411690-26-000044). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [6,073](/filings/0001411690-25-000093.md) | [8,163 d](/filings/0001411690-26-000007.md) | [6,457](/filings/0001411690-26-000028.md) | [6,733](/filings/0001411690-26-000044.md) | [7,367](/filings/0001411690-25-000093.md) | [7,951 d](/filings/0001411690-26-000007.md) | [6,687](/filings/0001411690-26-000028.md) | [8,171](/filings/0001411690-26-000044.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(722.9%)](/filings/0001411690-25-000093.md) | [(146.3%) d](/filings/0001411690-26-000007.md) | [(131.1%)](/filings/0001411690-26-000028.md) | [(115.8%)](/filings/0001411690-26-000044.md) | [(115.9%)](/filings/0001411690-25-000093.md) | [(107.4%) d](/filings/0001411690-26-000007.md) | [(118.1%)](/filings/0001411690-26-000028.md) | [(88.3%)](/filings/0001411690-26-000044.md) | | Net margin | % | [(728.6%)](/filings/0001411690-25-000093.md) | [(246.5%) d](/filings/0001411690-26-000007.md) | [(48.0%)](/filings/0001411690-26-000044.md) | [(101.8%)](/filings/0001411690-26-000044.md) | [(115.4%)](/filings/0001411690-25-000093.md) | [(99.8%) d](/filings/0001411690-26-000007.md) | [(124.2%)](/filings/0001411690-26-000044.md) | [(90.8%)](/filings/0001411690-26-000044.md) | | Diluted EPS | $ per share | [(30.92)](/filings/0001411690-25-000093.md) | not reported | [(1.15)](/filings/0001411690-26-000028.md) | [(1.99)](/filings/0001411690-26-000044.md) | [(1.59)](/filings/0001411690-25-000093.md) | not reported | [(0.76)](/filings/0001411690-26-000028.md) | [(0.64)](/filings/0001411690-26-000044.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.0](/filings/0001411690-23-000010.md) | [27.8](/filings/0001411690-24-000013.md) | [36.1](/filings/0001411690-25-000037.md) | [30.8](/filings/0001411690-26-000007.md) | [28.5](/filings/0001411690-26-000007.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(428.8%)](/filings/0001411690-23-000010.md) | [(473.7%)](/filings/0001411690-24-000013.md) | [(596.0%)](/filings/0001411690-25-000037.md) | [(337.9%)](/filings/0001411690-26-000007.md) | [(116.9%)](/filings/0001411690-26-000007.md) | | Net margin | % | [(402.8%)](/filings/0001411690-23-000010.md) | [(476.9%)](/filings/0001411690-24-000013.md) | [(643.7%)](/filings/0001411690-25-000037.md) | [(364.0%)](/filings/0001411690-26-000007.md) | [(92.6%)](/filings/0001411690-26-000007.md) | | Diluted EPS | $ per share | [(0.26)](/filings/0001411690-23-000010.md) | [(4.58)](/filings/0001411690-24-000013.md) | [(408.60)](/filings/0001411690-25-000037.md) | [(88.13)](/filings/0001411690-26-000007.md) | [(4.85)](/filings/0001411690-26-000007.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bngo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CARRET ASSET MANAGEMENT, LLC](/funds/791490.md) | 2026-06-30 | $141.3k | 125,000 | | Added +55,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $101.7k | 89,993 | | Reduced −77,540 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $93.1k | 82,388 | | Added +14,279 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $58.3k | 51,578 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $57.7k | 51,100 | | Added +2,400 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $40.4k | 35,728 | | New +35,728 | | [PRUDENTIAL FINANCIAL INC](/funds/1137774.md) | 2026-06-30 | $35.7k | 31,600 | | Added +3,600 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $27.8k | 24,561 | | Added +4,042 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $18.4k | 16,295 | | New +16,295 | | [Engineers Gate Manager LP](/funds/1620220.md) | 2026-06-30 | $13.5k | 11,988 | | Added +135 | ## Recent filings [All 624 filings](/companies/bngo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 17:13 ET | [S-1](/filings/0001193125-26-434439.md) | Registration statement | 0001193125-26-434439 | | 2026-09-14 | 08:30 ET | [8-K](/filings/0001411690-26-000046.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001411690-26-000046 | | 2026-08-10 | 16:10 ET | [10-Q](/filings/0001411690-26-000044.md) | Quarterly report, period 2026-06-30 | 0001411690-26-000044 | | 2026-08-10 | 16:05 ET | [8-K](/filings/0001411690-26-000043.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001411690-26-000043 | | 2026-06-24 | 08:30 ET | [8-K](/filings/0001411690-26-000040.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001411690-26-000040 | | 2026-06-05 | 16:00 ET | [8-K](/filings/0001411690-26-000036.md) | 5.02 Departure or appointment of officers or directors | 0001411690-26-000036 | | 2026-05-28 | 08:00 ET | [8-K](/filings/0001411690-26-000033.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001411690-26-000033 | | 2026-05-14 | 16:29 ET | [8-K](/filings/0001411690-26-000030.md) | 5.07 Shareholder vote results | 0001411690-26-000030 | | 2026-05-13 | 16:09 ET | [10-Q](/filings/0001411690-26-000028.md) | Quarterly report, period 2026-03-31 | 0001411690-26-000028 | | 2026-05-13 | 16:03 ET | [8-K](/filings/0001411690-26-000027.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001411690-26-000027 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001411690-26-000007.md), filed Mar 23, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/405d8c10-c84d-4953-96d6-ab9ee8b619c8) ## About the filer - CIK: 1411690 - Tickers: BNGO - Exchange: Nasdaq - SIC code: 3826 Laboratory Analytical Instruments - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:14 ET. No prices; not investment advice.